Compare Jones Lang LaSalle Inc (JLL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Merck & Co., Inc. — how do they compare? Jones Lang LaSalle Inc trades at $325.29 (market cap $15.12B), while Merck & Co., Inc. trades at $126.26 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 20.3× Jones Lang LaSalle Inc's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| JLL | MRK | |
|---|---|---|
Market Cap | $15.12B | $307.25B |
Sector | Real Estate | Health |
52-Week High | $358.66 | $129.52 |
52-Week Low | $253.48 | $77.60 |
Enterprise Value | $18.66B | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $324.44, down 1.88% today, with a bullish technical signal from moving averages and a consensus price target of $405.50 suggesting 25% upside. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $3.43 exceeding the $3.01 estimate. Revenue grew to $26.12B in 2025, and net income margin improved to 3.03%. Positive news highlights AI-driven real estate demand and major financing deals, reinforcing growth prospects.
The outlook for JLL is positive, supported by strong fundamentals, analyst upgrades, and strategic positioning in AI-impacted real estate markets. Key opportunities include continued earnings momentum and valuation upside, while risks involve economic sensitivity and competitive pressures in commercial real estate services.
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
